Literature DB >> 3758139

Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG).

K Griffiths, D G McDevitt, M Andrew, I Baksaas, A Helgeland, J Jervell, P K Lunde, K Oydvin, I Agenäs, U Bergman.   

Abstract

A questionnaire survey based on hypertension case histories was performed among a representative sample of 400 GP's and hospital doctors in Northern Ireland, Norway and Sweden, countries having markedly different utilization of antihypertensive drugs. We found a greater propensity to start antihypertensive drug treatment in Northern Ireland than in Norway and Sweden. This was true both in mild diastolic and isolated systolic hypertension. Yet the utilization of antihypertensive drugs in Sweden is about 60% higher than in Northern Ireland and 30% higher than in Norway. Swedish physicians preferred beta-blockers as their first choice to a greater extent than physicians in Northern Ireland and Norway who selected thiazides more often. In general, the choice of drugs agreed with the sales and prescribing patterns in the three countries. Besides providing more insight in therapeutic traditions the study indicates that the lower prescribing of antihypertensive drugs in Northern Ireland, and to some extent in Norway, compared to Sweden, might be due to differences in true or apparent morbidity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758139     DOI: 10.1007/BF00542409

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; M J Schwartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

2.  Hypertension in general practice: what is to be done?

Authors:  J Coope
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-24

3.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

4.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Five-year mortality in the city of Bergen, Norway, according to age, sex and blood pressure.

Authors:  I Holme; H T Waaler
Journal:  Acta Med Scand       Date:  1976

6.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

7.  Elevation of serum lipid levels during diuretic therapy of hypertension.

Authors:  R P Ames; P Hill
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

8.  Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.

Authors:  A Helgeland
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

9.  Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Authors:  P Leren; P O Foss; A Helgeland; I Hjermann; I Holme; P G Lund-Larsen
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

10.  Coronary heart-disease after treatment of hypertension.

Authors:  G Berglund; R Sannerstedt; O Andersson; H Wedel; L Wilhelmsen; L Hansson; R Sivertsson; J Wikstrand
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

View more
  13 in total

1.  Drug utilization in general practice: prescribing habits of National Formulary drugs by GPs of Emilia Romagna (Italy) in 1988 and 1989.

Authors:  N Montanaro; N Magrini; A Vaccheri; M Battilana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmaco-epidemiological perspectives.

Authors:  U Bergman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

3.  Pharmacoepidemiology and the "impact factor".

Authors:  Emilio J Sanz
Journal:  Eur J Clin Pharmacol       Date:  2004-12-03       Impact factor: 2.953

4.  The use of drugs in Estonia compared to the Nordic countries.

Authors:  R A Kiivet; U Bergman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Differences in antidiabetic drug utilisation between three different health systems in the same national region.

Authors:  J Benítez; A M Puerto; J A Díaz
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  On the differences in psychotropic drug use between the three major urban areas in Sweden.

Authors:  A Wessling; U Bergman; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

8.  Changes in the use of antibacterial drugs in the countries of central and eastern Europe.

Authors:  R A Kiivet; V Bíba; D Enache; V Foltan; J Gulbinovic; N Oltványi; A Orazem; M Popova; L Stika
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  How informed general practitioners manage mild hypertension: a survey of readers of drug bulletins in 7 countries. International Society of Drug Bulletins (ISDB).

Authors:  F Avanzini; G Tognoni; C Alli; F Colombo; A Herxheimer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.